Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left

A M E Spoelstra-de Man1, F J van Ittersum, M T Schram

  • 1Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.

Insights

Aggressive antihypertensive therapy significantly reduced left ventricular mass index and arterial stiffness in patients with type 2 diabetes. No specific drug strategy showed superiority, highlighting the importance of achieving blood pressure targets.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Hypertension and type 2 diabetes are significant risk factors for cardiovascular complications.
  • Left ventricular mass index (LVM) and arterial stiffness are key indicators of cardiovascular risk.
  • Aggressive blood pressure control is crucial in managing these conditions.

Purpose of the Study:

  • To investigate the impact of aggressive antihypertensive therapy on LVM index and arterial stiffness in hypertensive type II diabetic individuals.
  • To compare the efficacy of hydrochlorothiazide, candesartan, and lisinopril-based strategies.

Main Methods:

  • A randomized, double-blind, double-dummy study involving 70 hypertensive type II diabetic patients.
  • Three antihypertensive strategies were employed with blood pressure titrated to <130/85 mm Hg.
  • Patients were treated for 12 months, with assessments of LVM index and arterial stiffness.

Main Results:

  • Aggressive antihypertensive treatment led to significant improvements in LVM index and arterial stiffness across all groups.
  • No significant differences were observed between hydrochlorothiazide, candesartan, and lisinopril-based treatment strategies.
  • Approximately 70% of patients achieved target blood pressure levels, often requiring a median of three antihypertensive drugs.

Conclusions:

  • Aggressive antihypertensive therapy effectively reduces LVM index and arterial stiffness in hypertensive type II diabetic individuals.
  • Diuretic-based strategies are as effective as renin-angiotensin system inhibitor-based strategies in this patient population.
  • Achieving target blood pressure is paramount, though challenging, in mitigating cardiovascular risk.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...